Atuzaginstat Shows Potential in GAIN Trial Patients With Severe Gum Disease

Atuzaginstat Shows Potential in GAIN Trial Patients With Severe Gum Disease

310827

Atuzaginstat Shows Potential in GAIN Trial Patients With Severe Gum Disease

In a subset of patients with mild to moderate Alzheimer’s and evidence of severe gum disease due to P. gingivalis infection, treatment with atuzaginstat (COR388) appeared to slow their cognitive decline, according to results from the Phase 2/3 GAIN clinical trial. Across all treated study patients, however, atuzaginstat’s use over about one year failed to meet this primary trial goal, or its other main goal, that of improving daily life activities. While all patients in the GAIN study showed evidence…

You must be logged in to read/download the full post.